AI assistant
MYRIAD GENETICS INC — Director's Dealing 2025
Mar 17, 2025
32566_dirs_2025-03-17_712f15b8-3ab2-4db3-b2e8-36d82eb315c8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2025-03-13
Reporting Person: Verratti Mark (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-13 | Common Stock | A | 99227 | — | Acquired | 401262 | Direct |
| 2025-03-14 | Common Stock | F | 5847 | $10.07 | Disposed | 395415 | Direct |
| 2025-03-15 | Common Stock | F | 3729 | $10.07 | Disposed | 391686 | Direct |
Footnotes
F1: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.
F2: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025.